Literature DB >> 15055478

Insulin-like growth factor binding protein-3 mediates serum starvation- and doxorubicin-induced apoptosis in H9c2 cardiac cells.

R Granata1, M De Petrini, L Trovato, R Ponti, N Pons, C Ghè, A Graziani, R J Ferry, G Muccioli, E Ghigo.   

Abstract

Insulin-like growth factor binding protein 3 (IGFBP-3) modulates the activity of IGF-I, which exerts antiapoptotic action upon the myocardiocyte. IGFBP-3 also exerts IGF-independent actions to inhibit cell growth and induce apoptosis, mediating the effects of several antiproliferative agents. We hypothesized that IGFBP-3 mediates cardiomyocyte apoptosis. IGFBP-3 expression was studied in H9c2 rat cardiac cells cultured in serum-deprived medium in the absence or presence of 1 microM doxorubicin during a 72 h time-span. To a greater degree than serum withdrawal, doxorubicin induced IGFBP-3 up-regulation that was time-dependent. IGFBP-3 mRNA levels positively correlated with the degree of apoptosis. Exogenous IGFBP-3 decreased cell viability and induced apoptosis in serum-starved cells exposed to doxorubicin. IGFBP-3 antisense oligonucleotides markedly decreased apoptosis induced by either serum withdrawal or doxorubicin. Binding studies revealed specific high-affinity sites for IGFBP-3 in H9c2 cardiomyocytes, with binding characteristics typical of receptor-ligand interactions. These findings indicate that IGFBP-3 could play proapoptotic action at the myocardial level and suggest a novel role for this protein in cardiovascular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15055478     DOI: 10.1007/BF03349163

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  45 in total

1.  Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner.

Authors:  Z P Gill; C M Perks; P V Newcomb; J M Holly
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  Properties of a clonal muscle cell line from rat heart.

Authors:  B W Kimes; B L Brandt
Journal:  Exp Cell Res       Date:  1976-03-15       Impact factor: 3.905

Review 3.  Death by design. Programmed cell death in cardiovascular biology and disease.

Authors:  W R MacLellan; M D Schneider
Journal:  Circ Res       Date:  1997-08       Impact factor: 17.367

Review 4.  Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3.

Authors:  L S Phillips; C I Pao; B C Villafuerte
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1998

5.  Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells.

Authors:  L Wang; W Ma; R Markovich; W L Lee; P H Wang
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

6.  Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria.

Authors:  C M Perks; C McCaig; J M Holly
Journal:  J Cell Biochem       Date:  2000-10-20       Impact factor: 4.429

7.  Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule.

Authors:  Y Yamanaka; J L Fowlkes; E M Wilson; R G Rosenfeld; Y Oh
Journal:  Endocrinology       Date:  1999-03       Impact factor: 4.736

8.  Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.

Authors:  G L Francis; M Ross; F J Ballard; S J Milner; C Senn; K A McNeil; J C Wallace; R King; J R Wells
Journal:  J Mol Endocrinol       Date:  1992-06       Impact factor: 5.098

9.  IGFBP-3 mediates p53-induced apoptosis during serum starvation.

Authors:  Adda Grimberg; Bingrong Liu; Peter Bannerman; Wafik S El-Deiry; Pinchas Cohen
Journal:  Int J Oncol       Date:  2002-08       Impact factor: 5.650

10.  Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT.

Authors:  Gianluca Baldanzi; Nicoletta Filigheddu; Santina Cutrupi; Filomena Catapano; Sara Bonissoni; Alberto Fubini; Daniela Malan; Germano Baj; Riccarda Granata; Fabio Broglio; Mauro Papotti; Nicola Surico; Federico Bussolino; Jorgen Isgaard; Romano Deghenghi; Fabiola Sinigaglia; Maria Prat; Giampiero Muccioli; Ezio Ghigo; Andrea Graziani
Journal:  J Cell Biol       Date:  2002-12-16       Impact factor: 10.539

View more
  5 in total

1.  EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I.

Authors:  Munenori Takaoka; Caitlin E Smith; Michael K Mashiba; Takaomi Okawa; Claudia D Andl; Wafik S El-Deiry; Hiroshi Nakagawa
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-10-06       Impact factor: 4.052

Review 2.  Nuclear actions of insulin-like growth factor binding protein-3.

Authors:  Robert C Baxter
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

3.  Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage.

Authors:  Melissa W Y Chua; Mike Z Lin; Janet L Martin; Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

4.  Doxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytes.

Authors:  Patrizia Fabbi; Paolo Spallarossa; Silvano Garibaldi; Chiara Barisione; Marzia Mura; Paola Altieri; Barbara Rebesco; Maria Gaia Monti; Marco Canepa; Giorgio Ghigliotti; Claudio Brunelli; Pietro Ameri
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

5.  Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage.

Authors:  Kamila A Marzec; Mike Z Lin; Janet L Martin; Robert C Baxter
Journal:  Oncotarget       Date:  2015-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.